Conivaptan: A step forward in the treatment of hyponatremia?

Su Su Hline, Phuong-truc Thi Pham, Phuong Thu T. Pham, May H. Aung, Phuong Mai T. Pham, Phuong Chi T. Pham

Research output: Contribution to journalReview article

13 Citations (Scopus)

Abstract

Hyponatremia is one of the most common electrolyte abnormalities linked to adverse outcomes and increased mortality in hospitalized patients. While the differential diagnosis for hyponatremia is diverse, most cases stem from arginine vasopressin (AVP) dysregulation, where hypoosmolality fails to suppress AVP synthesis and release. The physiological effects of AVP are currently known to depend on its interaction with any of 3 receptor subtypes VIA,. V2, and V1B. Activation of V2 by AVP is the key in renal water regulation and maintenance of total body volume and plasma tonicity. Despite the long-recognized problem with excess AVP in euvolemic and hypervolemic hyponatremia, traditional therapeutic options have relied on nonspecific and potentially problematic strategies. More recently, a new class of drugs, introduced as "aquaretics," has gained great attention among clinicians because of its ability to correct hyponatremia via direct competitive inhibition of AVP at V2 receptors to induce renal electrolyte-free water excretion. In this paper, we aim to review available clinical data on the only FDA-approved aquaretic, dual V1A/V2 receptor antagonist conivaptan, discuss its clinical indications, efficacy, safety profile, and comment on its clinical limitations.

Original languageEnglish (US)
Pages (from-to)315-326
Number of pages12
JournalTherapeutics and Clinical Risk Management
Volume4
Issue number2
StatePublished - May 27 2008

Fingerprint

Arginine
Hyponatremia
Arginine Vasopressin
water
activation
indication
Vasopressin Receptors
mortality
drug
regulation
Electrolytes
ability
Therapeutics
interaction
Kidney
Water
Plasma Volume
conivaptan
Differential Diagnosis
Chemical activation

All Science Journal Classification (ASJC) codes

  • Safety Research
  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Pharmacology (medical)
  • Chemical Health and Safety

Cite this

Hline, S. S., Pham, P. T., Pham, P. T. T., Aung, M. H., Pham, P. M. T., & Pham, P. C. T. (2008). Conivaptan: A step forward in the treatment of hyponatremia? Therapeutics and Clinical Risk Management, 4(2), 315-326.
Hline, Su Su ; Pham, Phuong-truc Thi ; Pham, Phuong Thu T. ; Aung, May H. ; Pham, Phuong Mai T. ; Pham, Phuong Chi T. / Conivaptan : A step forward in the treatment of hyponatremia?. In: Therapeutics and Clinical Risk Management. 2008 ; Vol. 4, No. 2. pp. 315-326.
@article{f5f10bde5f8845c6aaf1eaf40ddc6797,
title = "Conivaptan: A step forward in the treatment of hyponatremia?",
abstract = "Hyponatremia is one of the most common electrolyte abnormalities linked to adverse outcomes and increased mortality in hospitalized patients. While the differential diagnosis for hyponatremia is diverse, most cases stem from arginine vasopressin (AVP) dysregulation, where hypoosmolality fails to suppress AVP synthesis and release. The physiological effects of AVP are currently known to depend on its interaction with any of 3 receptor subtypes VIA,. V2, and V1B. Activation of V2 by AVP is the key in renal water regulation and maintenance of total body volume and plasma tonicity. Despite the long-recognized problem with excess AVP in euvolemic and hypervolemic hyponatremia, traditional therapeutic options have relied on nonspecific and potentially problematic strategies. More recently, a new class of drugs, introduced as {"}aquaretics,{"} has gained great attention among clinicians because of its ability to correct hyponatremia via direct competitive inhibition of AVP at V2 receptors to induce renal electrolyte-free water excretion. In this paper, we aim to review available clinical data on the only FDA-approved aquaretic, dual V1A/V2 receptor antagonist conivaptan, discuss its clinical indications, efficacy, safety profile, and comment on its clinical limitations.",
author = "Hline, {Su Su} and Pham, {Phuong-truc Thi} and Pham, {Phuong Thu T.} and Aung, {May H.} and Pham, {Phuong Mai T.} and Pham, {Phuong Chi T.}",
year = "2008",
month = "5",
day = "27",
language = "English (US)",
volume = "4",
pages = "315--326",
journal = "Therapeutics and Clinical Risk Management",
issn = "1176-6336",
publisher = "Dove Medical Press Ltd.",
number = "2",

}

Hline, SS, Pham, PT, Pham, PTT, Aung, MH, Pham, PMT & Pham, PCT 2008, 'Conivaptan: A step forward in the treatment of hyponatremia?', Therapeutics and Clinical Risk Management, vol. 4, no. 2, pp. 315-326.

Conivaptan : A step forward in the treatment of hyponatremia? / Hline, Su Su; Pham, Phuong-truc Thi; Pham, Phuong Thu T.; Aung, May H.; Pham, Phuong Mai T.; Pham, Phuong Chi T.

In: Therapeutics and Clinical Risk Management, Vol. 4, No. 2, 27.05.2008, p. 315-326.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Conivaptan

T2 - A step forward in the treatment of hyponatremia?

AU - Hline, Su Su

AU - Pham, Phuong-truc Thi

AU - Pham, Phuong Thu T.

AU - Aung, May H.

AU - Pham, Phuong Mai T.

AU - Pham, Phuong Chi T.

PY - 2008/5/27

Y1 - 2008/5/27

N2 - Hyponatremia is one of the most common electrolyte abnormalities linked to adverse outcomes and increased mortality in hospitalized patients. While the differential diagnosis for hyponatremia is diverse, most cases stem from arginine vasopressin (AVP) dysregulation, where hypoosmolality fails to suppress AVP synthesis and release. The physiological effects of AVP are currently known to depend on its interaction with any of 3 receptor subtypes VIA,. V2, and V1B. Activation of V2 by AVP is the key in renal water regulation and maintenance of total body volume and plasma tonicity. Despite the long-recognized problem with excess AVP in euvolemic and hypervolemic hyponatremia, traditional therapeutic options have relied on nonspecific and potentially problematic strategies. More recently, a new class of drugs, introduced as "aquaretics," has gained great attention among clinicians because of its ability to correct hyponatremia via direct competitive inhibition of AVP at V2 receptors to induce renal electrolyte-free water excretion. In this paper, we aim to review available clinical data on the only FDA-approved aquaretic, dual V1A/V2 receptor antagonist conivaptan, discuss its clinical indications, efficacy, safety profile, and comment on its clinical limitations.

AB - Hyponatremia is one of the most common electrolyte abnormalities linked to adverse outcomes and increased mortality in hospitalized patients. While the differential diagnosis for hyponatremia is diverse, most cases stem from arginine vasopressin (AVP) dysregulation, where hypoosmolality fails to suppress AVP synthesis and release. The physiological effects of AVP are currently known to depend on its interaction with any of 3 receptor subtypes VIA,. V2, and V1B. Activation of V2 by AVP is the key in renal water regulation and maintenance of total body volume and plasma tonicity. Despite the long-recognized problem with excess AVP in euvolemic and hypervolemic hyponatremia, traditional therapeutic options have relied on nonspecific and potentially problematic strategies. More recently, a new class of drugs, introduced as "aquaretics," has gained great attention among clinicians because of its ability to correct hyponatremia via direct competitive inhibition of AVP at V2 receptors to induce renal electrolyte-free water excretion. In this paper, we aim to review available clinical data on the only FDA-approved aquaretic, dual V1A/V2 receptor antagonist conivaptan, discuss its clinical indications, efficacy, safety profile, and comment on its clinical limitations.

UR - http://www.scopus.com/inward/record.url?scp=44049094699&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=44049094699&partnerID=8YFLogxK

M3 - Review article

C2 - 18728836

AN - SCOPUS:44049094699

VL - 4

SP - 315

EP - 326

JO - Therapeutics and Clinical Risk Management

JF - Therapeutics and Clinical Risk Management

SN - 1176-6336

IS - 2

ER -

Hline SS, Pham PT, Pham PTT, Aung MH, Pham PMT, Pham PCT. Conivaptan: A step forward in the treatment of hyponatremia? Therapeutics and Clinical Risk Management. 2008 May 27;4(2):315-326.